Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

[1]  R. Fuleihan,et al.  Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases , 2019, Pediatric Rheumatology.

[2]  C. Bodemer,et al.  Myogenic Progenitor Cells Exhibit Type I Interferon–Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis , 2018, Arthritis & rheumatology.

[3]  G. Shaddick,et al.  Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort , 2017, Journal of autoimmunity.

[4]  L. Christopher‐Stine,et al.  Immune-mediated necrotizing myopathy associated with statins: history and recent developments , 2017, Current opinion in rheumatology.

[5]  E. Chew.  Regulatory pathways implicated in male androgenetic alopecia pathogenesis , 2017, The British journal of dermatology.

[6]  S. Otto,et al.  Infections and vaccinations as possible triggers of inflammatory myopathies , 2017, Muscle & nerve.

[7]  C. Bodemer,et al.  P.197 Myogenic progenitor cells exhibit IFN type I-driven pro-angiogenic properties and molecular signature during juvenile dermatomyositis , 2017, Neuromuscular Disorders.

[8]  A. Bello,et al.  Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors , 2017, Journal of clinical pharmacology.

[9]  I. Bruce,et al.  Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. , 2017, Seminars in arthritis and rheumatism.

[10]  F. Miller,et al.  Environmental factors associated with disease flare in juvenile and adult dermatomyositis , 2017, Rheumatology.

[11]  Fengchun Zhang,et al.  Pregnancy in polymyositis or dermatomyositis: retrospective results from a tertiary centre in China , 2017, Rheumatology.

[12]  A. Mammen,et al.  Association of Anti–3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients , 2017, Arthritis care & research.

[13]  L. Pachman,et al.  Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity , 2017, RMD Open.

[14]  J. Stübgen.  Juvenile dermatomyositis/polymyositis and lymphoma , 2017, Journal of the Neurological Sciences.

[15]  H. Kim,et al.  Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America , 2017, Pediatric Rheumatology.

[16]  Lu Liang,et al.  Climate change and human infectious diseases: A synthesis of research findings from global and spatio-temporal perspectives. , 2017, Environment international.

[17]  P. Meroni,et al.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review , 2017, Clinical Reviews in Allergy & Immunology.

[18]  Michael F. Holick,et al.  The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention , 2017, Reviews in Endocrine and Metabolic Disorders.

[19]  Chiang-Ching Huang,et al.  Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study , 2017, Pediatric Rheumatology.

[20]  J. Lünemann,et al.  Immune and myodegenerative pathomechanisms in inclusion body myositis , 2017, Annals of clinical and translational neurology.

[21]  Min-Yuan Wu,et al.  Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia , 2017, Oncotarget.

[22]  H. T. Fuzii,et al.  Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review , 2017, Clinical Rheumatology.

[23]  Susan Kim,et al.  Race, Income, and Disease Outcomes in Juvenile Dermatomyositis , 2017, The Journal of pediatrics.

[24]  C. Huard,et al.  Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis , 2017, The British journal of dermatology.

[25]  I. Lundberg,et al.  Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study , 2017, Rheumatology.

[26]  P. Lachenbruch,et al.  2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis , 2017, Annals of the rheumatic diseases.

[27]  E. Smolewska,et al.  In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis—Are We Getting Closer to Personalised Medicine? , 2017, Current Rheumatology Reports.

[28]  M. Cordova,et al.  The family impact of caring for a child with juvenile dermatomyositis , 2017, Chronic illness.

[29]  L. Rider,et al.  Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease , 2017, Pediatric Rheumatology.

[30]  C. Mathieu,et al.  Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept , 2017, Reviews in Endocrine and Metabolic Disorders.

[31]  B. Feldman,et al.  Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash , 2017, The Journal of Rheumatology.

[32]  C. Crowson,et al.  Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis , 2017, The Journal of Rheumatology.

[33]  K. Lackner,et al.  Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase , 2016, Annals of the rheumatic diseases.

[34]  Chiang-Ching Huang,et al.  Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography , 2016, Pediatric Rheumatology.

[35]  J. Wilmshurst,et al.  Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study , 2016, Pediatric Rheumatology.

[36]  I. Lundberg,et al.  Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. , 2016, Rheumatology.

[37]  S. Tansley.  Antibodies in juvenile-onset myositis , 2016, Current opinion in rheumatology.

[38]  T. Jacques,et al.  Muscle Biopsy Findings in Combination With Myositis‐Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis , 2016, Arthritis & rheumatology.

[39]  J. Haas,et al.  Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases , 2016, Pediatric Rheumatology.

[40]  T. Takken,et al.  Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. , 2016, Rheumatology.

[41]  A. Engel,et al.  Microvascular alterations and the role of complement in dermatomyositis. , 2016, Brain : a journal of neurology.

[42]  L. Rider,et al.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes , 2016, Journal of internal medicine.

[43]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[44]  R. Martin,et al.  Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. , 2016, Environmental research.

[45]  L. Wedderburn,et al.  174 A diagnostic and treatment challenge: the prevalence and clinical associations of anti-HMG-CoA reductase autoantibodies in a large UK juvenile-onset myositis cohort , 2016 .

[46]  C. Wouters,et al.  Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial , 2016, The Lancet.

[47]  Chiang-Ching Huang,et al.  MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis , 2016, The Journal of Rheumatology.

[48]  L. Wedderburn,et al.  Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes , 2015, Current opinion in rheumatology.

[49]  I. Sjaastad,et al.  In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset. , 2015, Rheumatology.

[50]  L. Padyukov,et al.  Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis , 2015, Annals of the rheumatic diseases.

[51]  M. van Brussel,et al.  Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis , 2015, Arthritis & rheumatology.

[52]  T. Brannagan,et al.  Neuromuscular complications of hematopoietic stem cell transplantation , 2015, Muscle & nerve.

[53]  A. Tournadre,et al.  Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets , 2015, International journal of rheumatic diseases.

[54]  C. Crowson,et al.  Biologic predictors of clinical improvement in rituximab-treated refractory myositis , 2015, BMC Musculoskeletal Disorders.

[55]  C. Gieger,et al.  Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups , 2015, Annals of the rheumatic diseases.

[56]  T. Mimori,et al.  [Autoantibodies in myositis]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.

[57]  S. Takezaki,et al.  Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. , 2015, Rheumatology.

[58]  N. Chaiyakunapruk,et al.  Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand , 2015, PharmacoEconomics.

[59]  C. Tait,et al.  Mycophenolic acid in dermatology a century after its discovery , 2015, The Australasian journal of dermatology.

[60]  D. Roberts,et al.  Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. , 2015, Journal of autoimmunity.

[61]  A. Braga,et al.  Risk Factors for Juvenile Dermatomyositis: Exposure to Tobacco and Air Pollutants During Pregnancy , 2014, Arthritis care & research.

[62]  P. van der Torre,et al.  Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity , 2014, Annals of the rheumatic diseases.

[63]  V. Ricotti,et al.  Increased Presence of FOXP3+ Regulatory T Cells in Inflamed Muscle of Patients with Active Juvenile Dermatomyositis Compared to Peripheral Blood , 2014, PloS one.

[64]  B. Prakken,et al.  Correlation of CXCL10, Tumor Necrosis Factor Receptor Type II, and Galectin 9 With Disease Activity in Juvenile Dermatomyositis , 2014, Arthritis & rheumatology.

[65]  T. Jacques,et al.  Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study , 2014, Arthritis Research & Therapy.

[66]  G. Shaddick,et al.  Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset , 2014, Rheumatology.

[67]  Ling Lu,et al.  HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population , 2014, BMC Dermatology.

[68]  Chiang-Ching Huang,et al.  Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis , 2014, Arthritis care & research.

[69]  L. Servais,et al.  Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies , 2014, Medicine.

[70]  Andriy I. Bandos,et al.  Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis , 2014, Arthritis & rheumatology.

[71]  Annette Lee,et al.  Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. , 2013, Arthritis and rheumatism.

[72]  L. Rider,et al.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. , 2013, Rheumatic diseases clinics of North America.

[73]  Chiang-Ching Huang,et al.  Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children , 2013, Arthritis care & research.

[74]  I. Sjaastad,et al.  In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity , 2013, Annals of the rheumatic diseases.

[75]  M. Rice,et al.  Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. , 2013, Arthritis and rheumatism.

[76]  M. Rice,et al.  The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies , 2013, Medicine.

[77]  L. Wedderburn,et al.  Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? , 2013, Arthritis Research & Therapy.

[78]  A. Zelenetz,et al.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. , 2013, Clinical lymphoma, myeloma & leukemia.

[79]  F. Nimmerjahn,et al.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system? , 2013, Nature Reviews Immunology.

[80]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[81]  L. Punzi,et al.  Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity—a Comprehensive Review , 2013, Clinical Reviews in Allergy & Immunology.

[82]  S. Amin,et al.  Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. , 2012, Arthritis and rheumatism.

[83]  H. Roschel,et al.  Exercise training in juvenile dermatomyositis , 2012, Arthritis care & research.

[84]  Brian M Feldman,et al.  Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference , 2012, Arthritis care & research.

[85]  R. Silverman,et al.  Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. , 2012, The Journal of pediatrics.

[86]  C. Rabinovich,et al.  Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. , 2012, The Journal of pediatrics.

[87]  Q. Nguyen,et al.  Faculty Opinions recommendation of Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2011 .

[88]  E. Baechler,et al.  Type I interferon pathway in adult and juvenile dermatomyositis , 2011, Arthritis research & therapy.

[89]  N. Stone,et al.  Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. , 2011, The Journal of pediatrics.

[90]  B. Feldman,et al.  Efficacy of intravenous Ig therapy in juvenile dermatomyositis , 2011, Annals of the rheumatic diseases.

[91]  C. Bodemer,et al.  Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry , 2011, The Journal of Rheumatology.

[92]  J. Jarvis,et al.  Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. , 2011, Archives of dermatology.

[93]  K. Weinberg,et al.  Anti-CD52 Antibody-Mediated Immune Ablation with Autologous Immune Recovery for the Treatment of Refractory Juvenile Polymyositis , 2011, Journal of Clinical Immunology.

[94]  T. Niewold,et al.  Familial Aggregation of Autoimmune Disease in Juvenile Dermatomyositis , 2011, Pediatrics.

[95]  M. Yamada,et al.  Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. , 2011, The Journal of pediatrics.

[96]  A. Mammen,et al.  Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. , 2011, Arthritis and rheumatism.

[97]  L. Pachman,et al.  Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease , 2011, The Journal of Rheumatology.

[98]  A. Doria,et al.  Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. , 2010, Rheumatology.

[99]  T. Niewold,et al.  Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. , 2010, The Journal of pediatrics.

[100]  L. Pachman,et al.  Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis , 2010, Arthritis care & research.

[101]  B. Feldman,et al.  Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey , 2010, The Journal of Rheumatology.

[102]  T. Niewold,et al.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. , 2010, Arthritis and rheumatism.

[103]  B. Lie,et al.  Long‐term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case–control study , 2010, Arthritis care & research.

[104]  M. Civelek,et al.  MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro , 2010, Proceedings of the National Academy of Sciences.

[105]  L. Pachman,et al.  Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. , 2010, Arthritis and rheumatism.

[106]  B. Feldman,et al.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference , 2010, Arthritis care & research.

[107]  N. Wulffraat,et al.  Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis , 2010, Scandinavian journal of rheumatology.

[108]  A. Mammen,et al.  Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. , 2009, Arthritis and rheumatism.

[109]  C. Oddis,et al.  Clinical and Serologic Characterization of an Argentine Pediatric Myositis Cohort: Identification of a Novel Autoantibody (anti-MJ) to a 142-kDa Protein , 2009, The Journal of Rheumatology.

[110]  L. Pachman,et al.  Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. , 2009, Arthritis and rheumatism.

[111]  A. Vallejo,et al.  Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. , 2009, Arthritis and rheumatism.

[112]  L. Kunkel,et al.  miRNAS in normal and diseased skeletal muscle , 2008, Journal of cellular and molecular medicine.

[113]  Yi-Wen Chen,et al.  Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis , 2008, BMC Immunology.

[114]  B. Feldman,et al.  Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood , 2008, The Lancet.

[115]  P. Woo,et al.  Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. , 2008, Rheumatology.

[116]  L. Pachman,et al.  Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. , 2008, The Journal of rheumatology.

[117]  B. Feldman,et al.  Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. , 2008, Rheumatology.

[118]  P. Blackshear,et al.  Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity , 2008, Medicine.

[119]  B. Feldman,et al.  Safety of Intravenous Immunoglobulin in the Treatment of Juvenile Dermatomyositis: Adverse Reactions Are Associated With Immunoglobulin A Content , 2008, Pediatrics.

[120]  L. Pachman,et al.  Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. , 2008, Arthritis and rheumatism.

[121]  A. Paller,et al.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. , 2008, Arthritis and rheumatism.

[122]  W. Ollier,et al.  HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. , 2007, Rheumatology.

[123]  L. Wedderburn,et al.  Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. , 2007, Rheumatology.

[124]  Honglin Li,et al.  Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease. , 2007, Clinical immunology.

[125]  C. Weinberg,et al.  Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. , 2007, Arthritis and rheumatism.

[126]  G. Pruijn,et al.  C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome. , 2007, Arthritis and rheumatism.

[127]  S. Stock,et al.  Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. , 2006, Arthritis and rheumatism.

[128]  A. Dyer,et al.  Duration of illness is an important variable for untreated children with juvenile dermatomyositis. , 2006, The Journal of pediatrics.

[129]  A. Dyer,et al.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. , 2005, Arthritis and rheumatism.

[130]  T. Levine.  Rituximab in the treatment of dermatomyositis: an open-label pilot study. , 2005, Arthritis and rheumatism.

[131]  A. Dyer,et al.  US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. , 2003, Arthritis and rheumatism.

[132]  R. Sundel,et al.  Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. , 2002, Journal of the American Academy of Dermatology.

[133]  Eric P. Hoffman,et al.  Gene Expression Profiling in DQA1*0501+ Children with Untreated Dermatomyositis: A Novel Model of Pathogenesis1 , 2002, The Journal of Immunology.

[134]  A. Gedalia,et al.  Anticardiolipin antibodies in childhood rheumatic disorders , 1998, Lupus.

[135]  Gherardi,et al.  Dermatomyositis‐like graft‐versus‐host disease , 1998, The British journal of dermatology.

[136]  N. Pourmand,et al.  The Zn2+ binding domain of the human Ro 52 kDa protein is a target for conformation-dependent autoantibodies. , 1998, Journal of autoimmunity.

[137]  Bernstein Rm.  Autoantibodies in myositis. , 1993, Bailliere's clinical neurology.

[138]  J. Friedman,et al.  Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. , 1986, Arthritis and rheumatism.

[139]  L. Pachman,et al.  Natural and antibody-dependent cellular cytotoxicity in children with systemic lupus erythematosus and juvenile dermatomyositis. , 1983, The Journal of rheumatology.

[140]  W. Crowe,et al.  Nailfold capillary abnormalities and clinical outcome in childhood dermatomyositis. , 1982, Arthritis and rheumatism.

[141]  O. Jonasson,et al.  INCREASED FREQUENCY OF HLA-B8 IN JUVENILE DERMATOMYOSITIS , 1977, The Lancet.

[142]  O. Jonasson,et al.  HLA-B8 IN JUVENILE DERMATOMYOSITIS , 1977, The Lancet.

[143]  S. Carpenter,et al.  The childhood type of dermatomyositis , 1976, Neurology.

[144]  B. Banker.  DERMATOMYOSITIS OF CHILDHOOD: ULTRASTRUCTURAL ALTERATIONS OF MUSCLE AND INTRAMUSCULAR BLOOD VESSELS , 1975, Journal of neuropathology and experimental neurology.

[145]  J. Holton,et al.  MUSCLE BIOPSY IN COMBINATION WITH MYOSITIS-SPECIFIC AUTOANTIBODIES AIDS PREDICTION OF OUTCOMES IN JUVENILE DERMATOMYOSITIS , 2016 .

[146]  E. Bonfá,et al.  Reduction of ovarian reserve in adult patients with dermatomyositis. , 2015, Clinical and experimental rheumatology.

[147]  J. Gottenberg,et al.  Incidence and prevalence of inflammatory myopathies: a systematic review. , 2015, Rheumatology.

[148]  L. Christopher‐Stine.  Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein , 2010 .

[149]  I. Targoff,et al.  Immunoprecipitation-western blot for proteins of low abundance. , 2009, Methods in molecular biology.

[150]  F. Miller,et al.  Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families, and Healthcare Providers , 2007 .

[151]  C. Lindsley,et al.  Adjunctive use of hydroxychloroquine in childhood dermatomyositis. , 1989, The Journal of rheumatology.

[152]  K. Stenger.  [Pathogenesis of dermatomyositis]. , 1950, Klinische Wochenschrift.